Amylyx Pharmaceuticals, Inc.
AMLX
Clasificación en acciones
#4378
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Precio por acción
$28.84
Capitalización bursátil
$3.62B
Cambio (1 día)
5.52%
Cambio (1 año)
87.63%
País
US
Comercio Amylyx Pharmaceuticals, Inc. (AMLX)
Categoría
Healthcare
Ganancias de Amylyx Pharmaceuticals, Inc. (AMLX)
Ganancias en Jun 2026 TTM: $-152.05M
Secondo gli ultimi rapporti finanziari di Amylyx Pharmaceuticals, Inc., gli utili attuali della società sono $-152.05M. Nel 2023, la società ha registrato un utile di $54.30M, un aumento con respecto a agli utili del 2022, che erano di $-197.60M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Amylyx Pharmaceuticals, Inc. desde 2019 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $-152.05M | -49.68% |
| 2024 | $-302.14M | -656.45% |
| 2023 | $54.30M | -127.48% |
| 2022 | $-197.60M | 124.72% |
| 2021 | $-87.93M | 107.97% |
| 2020 | $-42.28M | 208.25% |
| 2019 | $-13.72M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | -3,569.28% |
US
|
|
| $-3.09B | 1,930.31% |
US
|
|
| $-4.02B | 2,541.44% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,382.93% |
NL
|
